Protagonist Therapeutics (PTGX) EBITDA (2015 - 2026)
Protagonist Therapeutics (PTGX) posted EBITDA of -$3.6 million for Q1 2026, up 92.76% sequentially from -$50.4 million in Q4 2025, and up 81.11% YoY from -$2.0 million in Q1 2025.
Protagonist Therapeutics (PTGX) EBITDA (2015 - 2026) Analysis & Trends
Protagonist Therapeutics has reported EBITDA for 12 years, with the latest figure at -$3.6 million in Q1 2026.
- Quarterly EBITDA rose 81.11% year-over-year to -$3.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$142.5 million (down 623.31% YoY) and the FY2025 annual result came in at -$158.1 million, down 162.54% from the prior year.
- EBITDA advanced to -$3.6 million in Q1 2026 per PTGX's latest filing, from -$50.4 million in the prior quarter.
- Over five years, EBITDA peaked at $206.3 million in Q1 2024 and troughed at -$50.4 million in Q4 2025.
- A 5-year average of -$7.9 million and a median of -$36.5 million in 2022 frame the typical range for EBITDA.
- The sharpest annual moves came in 2024 and 2025: EBITDA surged 672.75% in 2024, then plunged 139.72% in 2025.
- Over 5 years, EBITDA stood at -$36.5 million in 2022, then surged by 163.12% to $23.0 million in 2023, then surged by 450.05% to $126.8 million in 2024, then slumped by 139.72% to -$50.4 million in 2025, then jumped by 92.76% to -$3.6 million in 2026.
- According to Business Quant data, EBITDA over the past three periods registered -$3.6 million, -$50.4 million, and -$46.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Protagonist Therapeutics | 10.03 Bn | 10.03 Bn | - | 158.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 158.77 Mn |
| Mar 31, 2026 | -3.65 Mn |
| Dec 31, 2025 | -50.36 Mn |
| Sep 30, 2025 | -46.42 Mn |
| Jun 30, 2025 | -42.04 Mn |
| Mar 31, 2025 | -19.31 Mn |
| Dec 31, 2024 | 126.78 Mn |
| Sep 30, 2024 | -41.45 Mn |
| Jun 30, 2024 | -38.79 Mn |
| Mar 31, 2024 | 206.31 Mn |
| Dec 31, 2023 | 23.05 Mn |
| Sep 30, 2023 | -38.33 Mn |
| Jun 30, 2023 | -42.35 Mn |
| Mar 31, 2023 | -36.02 Mn |
| Dec 31, 2022 | -36.52 Mn |
| Sep 30, 2022 | -32.30 Mn |
| Jun 30, 2022 | -41.44 Mn |
| Mar 31, 2022 | -21.11 Mn |
| Dec 31, 2021 | -37.02 Mn |
| Sep 30, 2021 | -33.93 Mn |